

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT an extraordinary general meeting (the “**EGM**”) of the holders of domestic invested shares (the “**Domestic Shares**”) of nominal value of RMB0.10 each and the holders of foreign invested shares (the “**H Shares**”) of nominal value of RMB0.10 each in Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) will be held at 9th Floor, Block A2, Tianda High-Tech Park, No. 80, The 4th Avenue, TEDA, Tianjin, the People’s Republic of China (the “**PRC**”) on Friday, 30 December 2022 at 10:00 a.m. to consider and, if thought fit, pass, with or without modifications, the resolutions set out below:

1. to consider and, if thought fit, pass with or without modifications, the following resolutions as ordinary resolutions:
 - (a) “**THAT** Ms. Sun Li be and is hereby re-elected as an executive Director of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”
 - (b) “**THAT** Mr. He Xin be and is hereby re-elected as an executive Director of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”
 - (c) “**THAT** Mr. Cao Aixin be and is hereby re-elected as a non-executive Director of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”

- (d) “**THAT** Ms. Li Xueying be and is hereby re-elected as a non-executive Director of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”
- (e) “**THAT** Mr. Li Ximing be and is hereby re-elected as a non-executive Director of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”
- (f) “**THAT** Mr. Li Xudong be and is hereby re-elected as an independent non-executive Director of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”
- (g) “**THAT** Mr. Wang Yongkang be and is hereby re-elected as an independent non-executive Director of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”
- (h) “**THAT** Ms. Gao Chun be and is hereby re-elected as an independent non-executive Director of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”
- (i) “**THAT** Ms. Yang Chunyan be and is hereby re-elected as a Supervisor of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”
- (j) “**THAT** Ms. Liu Jinyu be and is hereby re-elected as a Supervisor of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”
- (k) “**THAT** Mr. Liang Weitao be and is hereby re-elected as an independent Supervisor of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”

(l) “**THAT** Mr. Zhao Zhiyou be and is hereby re-elected as an independent Supervisor of the Company for a term commencing 1 January 2023 and ending on 31 December 2025 at such amount of remuneration and upon and subject to such terms and conditions as contained in a service contract to be entered into with the Company.”

(m) “**THAT** the Board of the Company is and hereby authorized to negotiate the remuneration and the terms and conditions of, and to sign the service contract with each of the proposed Directors and Supervisors on behalf of the Company in accordance with the Articles of Association of the Company, the relevant laws of the People’s Republic of China and the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited.”

2. to consider and, if thought fit, pass with or without modifications, the following resolution as a special resolution:

“**THAT** Article 20 to the Articles of Association of the Company be amended as the followings upon having obtained the approval of the Shareholders of the Company and the fulfilment of the filing requirements with the Administration of Industry and Commence:

The Company initiated the establishment and issued a total of 1,894,500,000 ordinary shares after several times of capital increase, including 697,500,000 Domestic Shares, representing 36.82% of the Company’s total issuable ordinary shares, and 1,197,000,000 overseas listed foreign shares, representing 63.18% of the Company’s total issuable ordinary shares.

The share capital structure of the Company is as follows: 1,894,500,000 ordinary shares, in which 697,500,000 shares are Domestic Shares, of which: (1) 14,000,000 shares are held by the promoter, Gu Hanqing. (2) 9,000,000 shares are held by the promoter, Xie Kehua. 674,500,000 shares are held by the other Domestic Shares holders. 1,197,000,000 shares are held by shareholders of overseas listed foreign shares.”

3. to consider and, if thought fit, pass with or without modifications, the following resolution as a special resolution:

“**THAT** Article 20 to the Articles of Association of the Company be amended as the followings upon having obtained the approval of the Shareholders of the Company and the fulfilment of the filing requirements with the Administration of Industry and Commence:

The scope of business of the Company shall be in accordance with the approval issued by the company registration authority of the People’s Republic of China.

General items: the development of medical researches and tests; sales of Category II medical devices; sales of Category I medical devices; manufacturing of Category I medical devices; research and development of biological organic fertilizers; research and development of compound micro-organism fertilizers; research and development of technology for bio-chemical products; sales of fertilizers; sales of agricultural machineries; sales of agricultural films; sales of feeds for fisheries and livestock industries; crop straw treatment and processing and utilization services; technology service, technology development, technology exchanges, technology transfer, technology promotion; elderly care service; nursing institution service (excluding medical service); health consultation service (excluding diagnose service); housekeeping service; conference and exhibition service; corporate image planning; advertisement preparation; advertisement publication; advertisement design and agency; sale of food (only pre-packaged food); sale of food through online channels (only pre-packaged food); sale of pre-packaged foods, dairy products, powdered infant formula, special medical formula food. (Other than those which are subject to approval in accordance with the law, operating activities can be commenced with business licence);

Licensed items: crop seeds operation (operations subject to approval in accordance with the law can only carry out operating activities after being approved by relevant departments, and the specific operations are subject to the approval or licenses of the relevant departments) (Not allowed to invest in the areas prohibited from foreign investment in the Negative List for Admission of Foreign Investment)”

By order of the Board

Tianjin TEDA Biomedical Engineering Company Limited

Sun Li

Chairman

Tianjin, the PRC

15 November 2022

Notes:

1. Any shareholder of the Company entitled to attend and vote at the meeting mentioned above is entitled to appoint one or more proxies to attend and vote at the meeting on his/her/its behalf in accordance with the Articles of Association of the Company. A proxy needs not be a shareholder of the Company.
2. In order to be valid, the proxy form of the holder of the H Shares of the Company and, if such proxy form is signed by a person under a power of attorney or other authority on behalf of the appointer, a notarially certified copy of that power of attorney or authority shall be deposited at Computershare Hong Kong Investor Services Limited of 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (the "**Company's Share Registrar**") not less than 24 hours before the time appointed for holding the meeting or 24 hours before the time appointed for taking the poll.

3. In order to be valid, the proxy form of the holder of the Domestic Shares of the Company and, if such proxy form is signed by a person under a power of attorney or other authority on behalf of the appointer, a notarially certified copy of that power of attorney or authority shall be deposited at the registered address of the Company not less than 24 hours before the time appointed for holding the meeting or 24 hours before the time appointed for taking the poll.
4. Shareholders of the Company or their proxies shall produce documents of their proof of identity when attending the meeting. Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
5. The register of the shareholders of the Company will be closed from 30 November 2022 to 30 December 2022 (both days inclusive), during which no transfer of shares will be registered. As regards holders of H Shares of the Company and in order to ascertain the entitlement to attendance at the above meeting, all properly completed transfer forms accompanied by the relevant share certificates must be lodged with the Company's Share Registrar not later than 4:30 p.m., 29 November 2022 for registration.
6. Shareholders of the Company who intend to attend the meeting mentioned above should notify in writing for attendance to the Company by hand, post or fax not later than 9 December 2022.
7. The registered address of the Company and the contact details of the Company are as follows:

No. 12 Tai Hua Road, The 5th Avenue, TEDA, Tianjin, the PRC
Fax No.: (8622) 5981 6909

As at the date of this announcement, the executive directors of the Company are Sun Li, Hao Zhihui and He Xin; the non-executive directors of the Company are Cao Aixin, Li Ximing and Li Xueying; the independent non-executive directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

The announcement will remain at the "Latest Company Announcements" page on the GEM website at www.hkgem.com for at least seven (7) days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.